Latent tuberculosis

QIAGEN expands business in Middle East with new regional headquarters and major projects

Retrieved on: 
Wednesday, January 3, 2024
EEMEA, Workforce, TST, TB, CDC, Policy, QCI, Medicine, Commercial, Infection, Cervical cancer, Marketing, QGEN, QIAGEN, WHO, Disease, HPV, Incidence, Latent tuberculosis, Language interpretation, Vaccination, QDI, BCG, Meningitis, Ministry, Public, World Health Organization, Memorandum of understanding, Patient, Bacteria, Gold

“At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.

Key Points: 
  • “At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.
  • To accommodate its growing regional presence and customer needs, QIAGEN will inaugurate its new regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024.
  • This office will further strengthen the company’s commitment to the Middle East and improve its ability to serve clients in the area.
  • The CDC and WHO endorse the use of QuantiFERON-TB Gold Plus in all settings to combat the global TB epidemic.

U.S. Infectious Respiratory Disease Diagnostics Market Report 2023: High Prevalence Of Infectious Respiratory Diseases Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 12, 2023
Health, Infectious Diseases, EUA, Chapter Four, ELISPOT, Prevalence, Urinary tract infection, COVID-19, Infection, Immunoassay, American Thoracic Society, USD, COVID-19 testing, Chapter Three, Scope, Government, CDC, Incidence, PerkinElmer, RSV, Non-governmental organization, Investment, Patient, Tuberculosis, Laboratory, Polymerase chain reaction, Mass vaccination, Diagnosis, Latent tuberculosis, RT, Pneumonia, Automation, Disease, Medical device, Vaccine, Pharmaceutical industry

However, the U.S. infectious respiratory disease diagnostics market is expected to be driven by technological advancements, an increase in the prevalence of infectious respiratory diseases, and high R&D investments by the key players, government, & NGOs to develop novel & innovative products to address the increased market demand.

Key Points: 
  • However, the U.S. infectious respiratory disease diagnostics market is expected to be driven by technological advancements, an increase in the prevalence of infectious respiratory diseases, and high R&D investments by the key players, government, & NGOs to develop novel & innovative products to address the increased market demand.
  • The introduction of innovative products used for disease diagnosis is anticipated to fuel the U.S. respiratory infectious disease market growth.
  • Thus, the increasing incidence of respiratory infections is expected to drive the U.S. infectious respiratory disease diagnostics market during the study period.
  • However, its share is expected to decline to 69.97% by 2030 due to the mass vaccination drives being conducted in the U.S., which, in turn, will reduce the rate of diseases
    Chapter 3 U.S. Infectious Respiratory Disease Diagnostics Market Variables, Trends, And Scope
    3.3.1 High Prevalence Of Infectious Respiratory Diseases In U.S.
    Chapter 4 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Product Type, 2018 - 2030 (USD Million)
    4.2 U.S. Infectious Respiratory Disease Diagnostics Market: Product Type Movement Analysis

Vietnam Tuberculosis Therapeutics Market Report to 2028 - Featuring Novartis Vietnam, Johnson & Johnson, Otsuka Pharmaceutical Vietnam JSC, Lupin and GSK Vietnam - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Infectious Diseases, Pharmaceutical, Health, TB, Therapy, First Line, Tuberculosis, Prevalence, Second line, Latent tuberculosis, Mycobacterium tuberculosis, NTP, Growth, Government, Patient, Investment, Drug development, Awareness, Death, Pharmaceutical industry

The Vietnam tuberculosis therapeutics market is anticipated to register a robust growth in the forecast period, 2023-2027.

Key Points: 
  • The Vietnam tuberculosis therapeutics market is anticipated to register a robust growth in the forecast period, 2023-2027.
  • Besides, increasing investments and grants for tuberculosis therapeutics are boosting the growth of the Vietnam tuberculosis therapeutics market.
  • Rising government measures and growing public awareness of communicable illnesses are also expected to fuel the Vietnam tuberculosis therapeutics market.
  • The Vietnam tuberculosis therapeutics market is segmented on the basis of disease type, therapy, competitive landscape, and regional distribution.

QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS

Retrieved on: 
Monday, November 29, 2021
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Infectious Diseases, Genetics, Other Health, Patient, Genetically modified bacteria, Latent tuberculosis, Automation, World Health Organization, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DiaSorin, Adoption, Protein, CEO, Sale, Death, Company, Hospital, NYSE, FTSE MIB, WHO, Partnership, World, Group, Tuberculin, Knowledge, Â, Workflow, SEC, Budget, Blood, IVD, Solution, PMA, U.S. Securities and Exchange Commission, DNA, Research, FTSE, List of life sciences, Marketing, RNA, LTBI, Molecular diagnostics, FDA, Life, DIA, XL, TB, QGEN, XS, Growth, Infection, Disease, IGRA, Food, Gold, Pharmaceutical industry, Medical device, Vaccine, Fine chemical, QIAGEN, DiaSorin, QIAGEN, DIASORIN

The addition of the LIAISON XS platform will open up new joint opportunities for us to reach new customer segments requiring lower-throughput options.

Key Points: 
  • The addition of the LIAISON XS platform will open up new joint opportunities for us to reach new customer segments requiring lower-throughput options.
  • Carlo Rosa, CEO of DiaSorin Group, commented: Today we announce the approval of our first PMA assay available on the LIAISON XS platform.
  • This solution is a key milestone of our LIAISON XS strategy in the U.S., where the test was already successfully launched in 2019 on our LIAISON XL platform.
  • LIAISON QuantiFERON-TB Gold Plus is an interferon-gamma release assay (IGRA) developed by QIAGEN and DiaSorin to offer streamlined laboratory automation for latent TB screening.

Global Latent Tuberculosis Infection Testing Market (2021 to 2025) - Insights & Forecast with Potential Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 29, 2021
Health, Infectious diseases, Tuberculosis, Medical specialties, Clinical medicine, Medicine, Mantoux test, Latent tuberculosis, Tuberculin, IGRA, Interferon gamma, TST, COVID-19, QuantiFERON

The "Global Latent Tuberculosis Infection (LTBI) Testing Market: Insights & Forecast with Potential Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Latent Tuberculosis Infection (LTBI) Testing Market: Insights & Forecast with Potential Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.
  • The global latent tuberculosis infection (LTBI) testing market is estimated to reach US$2.2 billion in 2025, witnessing growth at a CAGR of 5.89% for the period spanning from 2021 to 2025.
  • The latent tuberculosis infection testing market can be segmented on the basis of type, named as Tuberculin Skin Test (TST) and Interferon Gamma Released Assay (IGRA).
  • In the global latent tuberculosis testing market, the tuberculin skin test segment accounted for the higher share in 2020.

PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC

Retrieved on: 
Tuesday, March 9, 2021
Oncology, Software, Medical devices, Infectious diseases, Hardware, Data management, Consumer electronics, Science, Technology, Satellite, Biotechnology, Nanotechnology, Health, Consumer, Environment, Agriculture, Children, Natural Resources, Baby, Maternity, Engineering, Chemicals, Plastics, Stem cells, Manufacturing, Oil, Gas, Radiology, Pharmaceutical, Other Science, Energy, Tuberculosis, PerkinElmer, Medical specialties, T-SPOT.TB, Latent tuberculosis, Infectious diseases, Clinical medicine

PerkinElmer, Inc. , (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec).

Key Points: 
  • PerkinElmer, Inc. , (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec).
  • PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021.
  • Oxford Immunotecs global role in fighting tuberculosis, particularly its trademark product, the T-SPOT.TB test, and the operations it has built are remarkable, said Prahlad Singh, PerkinElmer president and chief executive officer.
  • Headquartered in Abingdon, UK, Oxford Immunotec is recognized as a global leader of proprietary test kits for latent tuberculosis.

Insights on the Latent TB Detection Global Market to 2027 - by Test, End-user and Geography

Retrieved on: 
Tuesday, February 9, 2021
Tuberculosis, Medical specialties, Clinical medicine, Medicine, Mantoux test, Latent tuberculosis, IGRA, Tuberculin, TST, QuantiFERON, Tuberculosis diagnosis

According to this report the global latent TB market is expected to reach $1,684.86 million in 2027 from $1,131.82 million in 2019.

Key Points: 
  • According to this report the global latent TB market is expected to reach $1,684.86 million in 2027 from $1,131.82 million in 2019.
  • Based on test, the latent TB detection market was segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA).
  • Therefore, the high prevalence of TB is driving the need for TB tests, in turn, propelling the growth of the latent TD detection market.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Worldwide Latent TB Detection Industry to 2027 - Government Initiatives to Promote Tuberculosis Detection are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, February 8, 2021
Health, Infectious diseases, Tuberculosis, Medical specialties, Medicine, Clinical medicine, Latent tuberculosis, Mantoux test, Tuberculin, IGRA, QuantiFERON, Tuberculosis diagnosis

According to this report the global latent TB market is expected to reach $1,684.86 million in 2027 from $1,131.82 million in 2019.

Key Points: 
  • According to this report the global latent TB market is expected to reach $1,684.86 million in 2027 from $1,131.82 million in 2019.
  • The growth of the market is attributed to the increasing prevalence of tuberculosis and government initiatives to promote tuberculosis detection.
  • Based on test, the latent TB detection market was segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA).
  • Therefore, the high prevalence of TB is driving the need for TB tests, in turn, propelling the growth of the latent TD detection market.

The Global Tuberculosis Drugs Market is expected to grow from USD 1,483.27 Million in 2018 to USD 2,182.39 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.67%

Retrieved on: 
Tuesday, April 28, 2020
Infectious diseases, Medical specialties, Medicine, Tuberculosis, Latent tuberculosis, Tuberculosis management, Tuberculosis in India

On the basis of Disease Type, the Global Tuberculosis Drugs Market is studied across Active TB and Latent TB.

Key Points: 
  • On the basis of Disease Type, the Global Tuberculosis Drugs Market is studied across Active TB and Latent TB.
  • On the basis of Drug Class, the Global Tuberculosis Drugs Market is studied across Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs.
  • What are the factors that affect the growth in the Global Tuberculosis Drugs Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Tuberculosis Drugs Market?

The Global Tuberculosis Diagnostics Market is expected to grow from USD 2,394.63 Million in 2018 to USD 3,459.42 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.39%

Retrieved on: 
Tuesday, April 28, 2020
Medicine, Medical specialties, Clinical medicine, Tuberculosis, Mantoux test, Mantoux, Tuberculosis in India, Latent tuberculosis

On the basis of Test Type, the Global Tuberculosis Diagnostics Market is studied across Drug-susceptibility Testing, Laboratory Methods, Mantoux Test, Nucleic Acid Testing, and Radiographic Methods.

Key Points: 
  • On the basis of Test Type, the Global Tuberculosis Diagnostics Market is studied across Drug-susceptibility Testing, Laboratory Methods, Mantoux Test, Nucleic Acid Testing, and Radiographic Methods.
  • What are the factors that affect the growth in the Global Tuberculosis Diagnostics Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Tuberculosis Diagnostics Market?
  • What are the modes of entering the Global Tuberculosis Diagnostics Market?